Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer : Preliminary results on late toxicity and quality of life
To present our preliminary observations on the late toxicity and quality of life (QOL) of patients treated with short-course intensity-modulated radiotherapy (SCIM-RT). Fifty-one patients were treated with SCIM-RT at the Cleveland Clinic Foundation between October 1998 and May 1999. The technique co...
Saved in:
Published in | International journal of radiation oncology, biology, physics Vol. 51; no. 4; pp. 988 - 993 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier
15.11.2001
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To present our preliminary observations on the late toxicity and quality of life (QOL) of patients treated with short-course intensity-modulated radiotherapy (SCIM-RT).
Fifty-one patients were treated with SCIM-RT at the Cleveland Clinic Foundation between October 1998 and May 1999. The technique consisted of intensity-modulated radiotherapy using 5 static fields (anterior, 2 laterals, and 2 anterior obliques). Inverse plans were generated by the Corvus treatment-planning system. The treatment delivery was performed with a dynamic multileaf collimator. A total of 70.0 Gy was prescribed in all cases at 2.5 Gy per fraction to be delivered in 28 fractions over 5 and a half weeks. The location of the prostate gland was verified and adjusted daily with the BAT transabdominal ultrasound system. The median follow-up was 18 months (range: 11 to 26 months). The Radiation Therapy Oncology Group (RTOG) scales were used to evaluate late toxicity. The Expanded Prostate Cancer Index Composite (EPIC) was used to evaluate QOL. A total of 24 patients completed the EPIC questionnaire at approximately 2 years after therapy (median time from treatment to questionnaire administration: 24 months; range: 21 to 26 months). The results from the EPIC questionnaires were compared to scores from 46 patients treated during the same time period with conformal radiotherapy (CRT) to 78 Gy at 2 Gy per fraction.
The dose was prescribed to an isodose line ranging from 82.0% to 90.0% (mean: 87.2%). The range of the individual prostate mean doses was 73.5 to 78.5 Gy (average: 75.3 Gy). To date, only 1 patient had Grade 1 late urinary toxicity. To date, only 4 patients had Grade 1 late rectal toxicity. No Grade 2 or 3 late urinary or rectal complications have occurred. The actuarial rectal bleeding rate observed at 18 months was 7%. There were no differences in scores from the urinary, bowel, hormonal, and overall QOL domains between SCIM-RT patients and patients treated with CRT. The overall physical and mental QOL scores were also nearly identical to scores reported for the general U.S. population.
Preliminary late toxicity results up to 2 years after SCIM-RT are encouraging, with a median follow-up of 18 months (range 11 to 26 months). Late toxicity assessed by the physicians using RTOG late toxicity scores has been excellent. QOL reported by the patients using the EPIC questionnaire reveals no difference between patients treated with high-dose CRT at standard fractionation and patients treated with SCIM-RT. SCIM-RT is an alternative method of dose escalation in the treatment of localized prostate cancer. The proposed schedule significantly increases convenience to patients due to the decrease in overall treatment time. |
---|---|
AbstractList | To present our preliminary observations on the late toxicity and quality of life (QOL) of patients treated with short-course intensity-modulated radiotherapy (SCIM-RT).
Fifty-one patients were treated with SCIM-RT at the Cleveland Clinic Foundation between October 1998 and May 1999. The technique consisted of intensity-modulated radiotherapy using 5 static fields (anterior, 2 laterals, and 2 anterior obliques). Inverse plans were generated by the Corvus treatment-planning system. The treatment delivery was performed with a dynamic multileaf collimator. A total of 70.0 Gy was prescribed in all cases at 2.5 Gy per fraction to be delivered in 28 fractions over 5 and a half weeks. The location of the prostate gland was verified and adjusted daily with the BAT transabdominal ultrasound system. The median follow-up was 18 months (range: 11 to 26 months). The Radiation Therapy Oncology Group (RTOG) scales were used to evaluate late toxicity. The Expanded Prostate Cancer Index Composite (EPIC) was used to evaluate QOL. A total of 24 patients completed the EPIC questionnaire at approximately 2 years after therapy (median time from treatment to questionnaire administration: 24 months; range: 21 to 26 months). The results from the EPIC questionnaires were compared to scores from 46 patients treated during the same time period with conformal radiotherapy (CRT) to 78 Gy at 2 Gy per fraction.
The dose was prescribed to an isodose line ranging from 82.0% to 90.0% (mean: 87.2%). The range of the individual prostate mean doses was 73.5 to 78.5 Gy (average: 75.3 Gy). To date, only 1 patient had Grade 1 late urinary toxicity. To date, only 4 patients had Grade 1 late rectal toxicity. No Grade 2 or 3 late urinary or rectal complications have occurred. The actuarial rectal bleeding rate observed at 18 months was 7%. There were no differences in scores from the urinary, bowel, hormonal, and overall QOL domains between SCIM-RT patients and patients treated with CRT. The overall physical and mental QOL scores were also nearly identical to scores reported for the general U.S. population.
Preliminary late toxicity results up to 2 years after SCIM-RT are encouraging, with a median follow-up of 18 months (range 11 to 26 months). Late toxicity assessed by the physicians using RTOG late toxicity scores has been excellent. QOL reported by the patients using the EPIC questionnaire reveals no difference between patients treated with high-dose CRT at standard fractionation and patients treated with SCIM-RT. SCIM-RT is an alternative method of dose escalation in the treatment of localized prostate cancer. The proposed schedule significantly increases convenience to patients due to the decrease in overall treatment time. To present our preliminary observations on the late toxicity and quality of life (QOL) of patients treated with short-course intensity-modulated radiotherapy (SCIM-RT). The dose was prescribed to an isodose line ranging from 82.0% to 90.0% (mean: 87.2%). The range of the individual prostate mean doses was 73.5 to 78.5 Gy (average: 75.3 Gy). To date, only 1 patient had Grade 1 late urinary toxicity. To date, only 4 patients had Grade 1 late rectal toxicity. No Grade 2 or 3 late urinary or rectal complications have occurred. The actuarial rectal bleeding rate observed at 18 months was 7%. There were no differences in scores from the urinary, bowel, hormonal, and overall QOL domains between SCIM-RT patients and patients treated with CRT. The overall physical and mental QOL scores were also nearly identical to scores reported for the general U.S. population. Preliminary late toxicity results up to 2 years after SCIM-RT are encouraging, with a median follow-up of 18 months (range 11 to 26 months). Late toxicity assessed by the physicians using RTOG late toxicity scores has been excellent. QOL reported by the patients using the EPIC questionnaire reveals no difference between patients treated with high-dose CRT at standard fractionation and patients treated with SCIM-RT. SCIM-RT is an alternative method of dose escalation in the treatment of localized prostate cancer. The proposed schedule significantly increases convenience to patients due to the decrease in overall treatment time. |
Author | WILLOUGHBY, Twyla R KLEIN, Eric A KUPELIAN, Patrick A REDDY, Chandana A |
Author_xml | – sequence: 1 givenname: Patrick A surname: KUPELIAN fullname: KUPELIAN, Patrick A organization: Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, United States – sequence: 2 givenname: Chandana A surname: REDDY fullname: REDDY, Chandana A organization: Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, United States – sequence: 3 givenname: Eric A surname: KLEIN fullname: KLEIN, Eric A organization: Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, United States – sequence: 4 givenname: Twyla R surname: WILLOUGHBY fullname: WILLOUGHBY, Twyla R organization: Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14103762$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11704322$$D View this record in MEDLINE/PubMed |
BookMark | eNpFkcFu1DAQhi1URLeFRwD5AmoPKeM4TrK9oQoKUiWQChKcLMceq0aOvbUdieV9eE8cuqKnmcP3z8z_zwk5CjEgIS8ZXDBg_dsMvIeG1_YM2DmwgUMzPiEbNg7bhgvx_Yhs_iPH5CTnnwDA2NA9I8e1QMfbdkP-3N7FVBodl5SRulAwZFf2zRzN4lVBQ5MyLpY7TGq3p2cD0OsfVBXaXoi122GiNildXAzn1MZEfdTKu99VuUsxlzqDahV05S7pl4TezS6otKcJ8-JLpjHQdREt8ZfTdTVVwdD7pc6ofbTUO4vPyVOrfMYXh3pKvn14__XqY3Pz-frT1bubRlc3pdmaycAEDHASaFB0ZuBKiW60pu1H2ymY-q1ABqDA8G4SfW9ZFQ2dGFEJy0_Jm4e59fT7BXORs8savVcB45IlG1vGxrGtoHgAdfWYE1q5S26utiQDuf5H3q7hyzV8CUz--48cq-7VYcEyzWgeVYeHVOD1AVC55lijDdrlR65jwIe-5X8Bt_Gcfw |
CODEN | IOBPD3 |
CitedBy_id | crossref_primary_10_1007_s00432_005_0681_0 crossref_primary_10_1016_j_ijrobp_2006_07_1386 crossref_primary_10_1016_j_ijrobp_2010_03_049 crossref_primary_10_1016_S0360_3016_02_02774_8 crossref_primary_10_1259_bjr_66104316 crossref_primary_10_1016_j_meddos_2007_01_004 crossref_primary_10_1080_02841860600710913 crossref_primary_10_1016_j_radonc_2009_03_004 crossref_primary_10_1186_s12885_019_6285_x crossref_primary_10_1016_j_prro_2014_10_007 crossref_primary_10_1016_S1507_1367_04_71013_5 crossref_primary_10_1186_1748_717X_2_29 crossref_primary_10_1200_JOP_2015_007385 crossref_primary_10_1007_s00066_009_1982_z crossref_primary_10_1002_14651858_CD011462_pub2 crossref_primary_10_1177_030089161009600112 crossref_primary_10_1093_jrr_rrw122 crossref_primary_10_1155_2014_470592 crossref_primary_10_1002_14651858_CD011462 crossref_primary_10_1186_s13014_019_1210_7 crossref_primary_10_1016_j_ijrobp_2007_01_067 crossref_primary_10_1016_j_ijrobp_2009_12_039 crossref_primary_10_1111_j_1464_410X_2008_08117_x crossref_primary_10_1007_s12672_024_00876_7 crossref_primary_10_1118_1_4712224 crossref_primary_10_1007_BF03178769 crossref_primary_10_1016_S1538_4721_02_00101_0 crossref_primary_10_1155_2012_853487 crossref_primary_10_1080_02841860600781781 crossref_primary_10_1186_1748_717X_8_206 crossref_primary_10_1177_153303461000900305 crossref_primary_10_1016_S0360_3016_03_00752_1 crossref_primary_10_1016_j_ijrobp_2003_09_001 crossref_primary_10_1177_153303460300200104 crossref_primary_10_1016_S1078_1439_02_00211_9 crossref_primary_10_18632_oncotarget_13735 crossref_primary_10_1016_j_ijrobp_2009_05_054 crossref_primary_10_3109_02841861003745535 crossref_primary_10_1016_j_clon_2016_02_005 crossref_primary_10_1016_j_ijrobp_2007_10_019 crossref_primary_10_1111_j_1743_7563_2012_01589_x crossref_primary_10_1016_j_ijrobp_2007_05_057 crossref_primary_10_3109_0284186X_2013_767983 crossref_primary_10_1017_S1460396919000694 crossref_primary_10_1016_j_ijrobp_2009_12_045 crossref_primary_10_1016_j_urology_2004_09_062 crossref_primary_10_1016_j_semradonc_2007_09_006 crossref_primary_10_1016_S0958_3947_02_00101_2 crossref_primary_10_1016_j_ijrobp_2008_07_024 crossref_primary_10_1016_j_radonc_2008_03_021 crossref_primary_10_1111_j_1463_1318_2005_00851_x crossref_primary_10_1016_j_ijrobp_2007_04_013 crossref_primary_10_1007_s11307_014_0755_y crossref_primary_10_1259_bjr_54028034 crossref_primary_10_1016_j_ijrobp_2009_06_024 crossref_primary_10_1016_j_radonc_2009_08_004 crossref_primary_10_1016_j_ijrobp_2005_05_010 crossref_primary_10_1016_j_ijrobp_2005_05_054 crossref_primary_10_1016_j_tipsro_2019_01_003 crossref_primary_10_1016_S1120_1797_05_80001_8 crossref_primary_10_1016_S1507_1367_10_60101_0 crossref_primary_10_5402_2012_410892 crossref_primary_10_1097_COC_0b013e3181841f13 crossref_primary_10_1120_jacmp_v8i3_2320 crossref_primary_10_1016_j_currproblcancer_2004_01_001 crossref_primary_10_1016_j_canrad_2011_05_005 crossref_primary_10_1177_153303460500400115 crossref_primary_10_1016_j_brachy_2014_05_001 crossref_primary_10_5301_RU_2013_11499 crossref_primary_10_1016_j_ijrobp_2004_12_017 crossref_primary_10_4111_kju_2006_47_11_1172 crossref_primary_10_1002_pros_22651 crossref_primary_10_1016_j_ijrobp_2010_05_027 crossref_primary_10_2217_14796694_3_6_649 crossref_primary_10_1177_030089160909500429 crossref_primary_10_1016_S0360_3016_03_00086_5 crossref_primary_10_1016_j_ijrobp_2004_07_695 crossref_primary_10_1016_j_radonc_2008_10_008 crossref_primary_10_1016_j_ijrobp_2006_02_039 crossref_primary_10_1093_jnci_djt462 crossref_primary_10_1016_j_prro_2017_03_012 crossref_primary_10_1200_JCO_2005_06_153 crossref_primary_10_2478_raon_2022_0011 crossref_primary_10_1155_2014_541847 crossref_primary_10_1016_j_brachy_2009_12_005 crossref_primary_10_1016_j_ijrobp_2008_02_030 crossref_primary_10_1016_j_prro_2020_02_013 crossref_primary_10_1007_s00066_009_1913_z crossref_primary_10_1016_j_ijrobp_2011_07_005 crossref_primary_10_1200_JCO_2013_51_1972 |
Cites_doi | 10.1016/S0360-3016(00)00591-5 10.1016/S0360-3016(00)80296-5 10.1002/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N 10.1016/S0360-3016(99)00454-X 10.1016/S0360-3016(99)00455-1 10.1016/S0090-4295(99)00389-1 10.1016/S0090-4295(00)00858-X 10.1016/S0090-4295(99)00380-5 10.1016/S0360-3016(00)80419-8 10.1016/S0360-3016(98)00438-6 10.1016/0360-3016(95)02103-5 10.1016/S0360-3016(96)00617-7 10.1016/S0360-3016(99)00498-8 10.3109/07853890008995911 |
ContentType | Journal Article |
Copyright | 2002 INIST-CNRS |
Copyright_xml | – notice: 2002 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U7 C1K |
DOI | 10.1016/s0360-3016(01)01730-8 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Toxicology Abstracts Environmental Sciences and Pollution Management |
DatabaseTitleList | MEDLINE Toxicology Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-355X |
EndPage | 993 |
ExternalDocumentID | 10_1016_S0360_3016_01_01730_8 11704322 14103762 |
Genre | Journal Article |
GroupedDBID | --- --K .1- .55 .FO .GJ 08R 0R~ 1B1 1P~ 1RT 1~5 29J 4.4 457 4G. 53G 5RE 5VS 7-5 AAEDT AAEDW AAIAV AALRI AAQFI AAQQT AAQXK AAUGY AAWTL AAXUO ABEFU ABLJU ABNEU ABOCM ABPTK ABUDA ACGFS ACIUM ADBBV ADMUD ADPAM AENEX AEVXI AFCTW AFFNX AFRHN AFTJW AGRDE AGZHU AHHHB AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS ALXNB AMRAJ ASPBG AVWKF AZFZN BELOY DU5 EBS EFJIC EJD F5P FDB FEDTE FGOYB FIRID G-2 GBLVA HED HMK HMO HX~ HZ~ IHE IQODW J1W KOM LX3 M41 MO0 NQ- O9- OC~ OO- R2- RIG RNS ROL RPZ SAE SDG SEL SES SEW SSZ UDS UV1 X7M XH2 XPP Z5R ZA5 ZGI ~S- ABJNI AKRWK CGR CUY CVF ECM EIF HVGLF NPM AAYXX ADVLN AFJKZ CITATION 7U7 C1K |
ID | FETCH-LOGICAL-c432t-9dbd0b010eb5ede54d73aa548fd268f4a0b695e100a0d34b566f19db7458ea5f3 |
ISSN | 0360-3016 |
IngestDate | Sat Oct 05 05:42:47 EDT 2024 Thu Sep 26 16:28:33 EDT 2024 Sat Sep 28 08:36:31 EDT 2024 Sun Oct 22 16:06:54 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Human Late Urinary system disease Iatrogenic Prognosis Prostate disease Male Malignant tumor Radiotherapy Quality of life Treatment Complication Male genital diseases Prostate |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c432t-9dbd0b010eb5ede54d73aa548fd268f4a0b695e100a0d34b566f19db7458ea5f3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 11704322 |
PQID | 18211882 |
PQPubID | 23462 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_18211882 crossref_primary_10_1016_S0360_3016_01_01730_8 pubmed_primary_11704322 pascalfrancis_primary_14103762 |
PublicationCentury | 2000 |
PublicationDate | 2001-11-15 |
PublicationDateYYYYMMDD | 2001-11-15 |
PublicationDate_xml | – month: 11 year: 2001 text: 2001-11-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | International journal of radiation oncology, biology, physics |
PublicationTitleAlternate | Int J Radiat Oncol Biol Phys |
PublicationYear | 2001 |
Publisher | Elsevier |
Publisher_xml | – name: Elsevier |
References | 12023157 - Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):512; author reply 512 Zelefsky (10.1016/S0360-3016(01)01730-8_BIB17) 1999; 85 Kupelian (10.1016/S0360-3016(01)01730-8_BIB18) 2000; 48 Ware (10.1016/S0360-3016(01)01730-8_BIB12) 1998 Kupelian (10.1016/S0360-3016(01)01730-8_BIB6) 2000; 46 Brenner (10.1016/S0360-3016(01)01730-8_BIB1) 2000; 48 Brenner (10.1016/S0360-3016(01)01730-8_BIB2) 1999; 43 Lyons (10.1016/S0360-3016(01)01730-8_BIB15) 2000; 55 Lattanzi (10.1016/S0360-3016(01)01730-8_BIB8) 2000; 55 Willoughby (10.1016/S0360-3016(01)01730-8_BIB10) 1999; 213 Wei (10.1016/S0360-3016(01)01730-8_BIB11) 2000; 56 Mohan (10.1016/S0360-3016(01)01730-8_BIB4) 2000; 46 Willoughby (10.1016/S0360-3016(01)01730-8_BIB9) 2000; 48 Hanks (10.1016/S0360-3016(01)01730-8_BIB13) 2000; 32 Hanks (10.1016/S0360-3016(01)01730-8_BIB14) 2000; 46 Katcher (10.1016/S0360-3016(01)01730-8_BIB5) 1997; 37 Pollack (10.1016/S0360-3016(01)01730-8_BIB16) 1999; 26 Duchesne (10.1016/S0360-3016(01)01730-8_BIB3) 1999; 44 Pollack (10.1016/S0360-3016(01)01730-8_BIB7) 1996; 34 |
References_xml | – volume: 48 start-page: 315 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB1 article-title: Toward optimal external-beam fractionation for prostate cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(00)00591-5 contributor: fullname: Brenner – year: 1998 ident: 10.1016/S0360-3016(01)01730-8_BIB12 contributor: fullname: Ware – volume: 44 start-page: 747 year: 1999 ident: 10.1016/S0360-3016(01)01730-8_BIB3 article-title: What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy publication-title: Int J Radiat Oncol Biol Phys contributor: fullname: Duchesne – volume: 26 start-page: 150 year: 1999 ident: 10.1016/S0360-3016(01)01730-8_BIB16 article-title: Prostate cancer treatment with radiotherapy publication-title: Semin Oncol contributor: fullname: Pollack – volume: 48 start-page: 250 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB18 article-title: Short course intensity modulated radiotherapy (70 Gy at 2.5 Gy per fraction) versus 3D-conformal radiotherapy (78 Gy at 2.0 Gy per fraction) for the treatment of localized prostate cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(00)80296-5 contributor: fullname: Kupelian – volume: 85 start-page: 2460 year: 1999 ident: 10.1016/S0360-3016(01)01730-8_BIB17 article-title: Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N contributor: fullname: Zelefsky – volume: 46 start-page: 575 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB4 article-title: Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(99)00454-X contributor: fullname: Mohan – volume: 46 start-page: 567 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB6 article-title: Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(99)00455-1 contributor: fullname: Kupelian – volume: 55 start-page: 73 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB8 article-title: Ultrasound-based stereotactic guidance of precision conformal external beam radiation therapy in clinically localized prostate cancer publication-title: Urology doi: 10.1016/S0090-4295(99)00389-1 contributor: fullname: Lattanzi – volume: 56 start-page: 899 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB11 article-title: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer publication-title: Urology doi: 10.1016/S0090-4295(00)00858-X contributor: fullname: Wei – volume: 55 start-page: 85 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB15 article-title: Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate publication-title: Urology doi: 10.1016/S0090-4295(99)00380-5 contributor: fullname: Lyons – volume: 48 start-page: 308 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB9 article-title: Daily transabdominal ultrasound localization of the prostate gland with the BAT system publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(00)80419-8 contributor: fullname: Willoughby – volume: 213 start-page: 110 year: 1999 ident: 10.1016/S0360-3016(01)01730-8_BIB10 article-title: Improvement in localization of prostate using a transabdominal ultrasound based system as assessed by implanted fiducial markers publication-title: Radiology contributor: fullname: Willoughby – volume: 43 start-page: 1095 year: 1999 ident: 10.1016/S0360-3016(01)01730-8_BIB2 article-title: Fractionation and protraction for radiotherapy of prostate carcinoma publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(98)00438-6 contributor: fullname: Brenner – volume: 34 start-page: 555 year: 1996 ident: 10.1016/S0360-3016(01)01730-8_BIB7 article-title: Conventional vs. conformal radiotherapy for prostate cancer publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/0360-3016(95)02103-5 contributor: fullname: Pollack – volume: 37 start-page: 871 year: 1997 ident: 10.1016/S0360-3016(01)01730-8_BIB5 article-title: Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(96)00617-7 contributor: fullname: Katcher – volume: 46 start-page: 823 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB14 article-title: Dose selection for prostate cancer patients based on dose comparison and dose response studies publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/S0360-3016(99)00498-8 contributor: fullname: Hanks – volume: 32 start-page: 57 year: 2000 ident: 10.1016/S0360-3016(01)01730-8_BIB13 article-title: Conformal radiotherapy for prostate cancer publication-title: Ann Med doi: 10.3109/07853890008995911 contributor: fullname: Hanks |
SSID | ssj0001174 |
Score | 2.0990863 |
Snippet | To present our preliminary observations on the late toxicity and quality of life (QOL) of patients treated with short-course intensity-modulated radiotherapy... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 988 |
SubjectTerms | Aged Aged, 80 and over Biological and medical sciences Dose Fractionation, Radiation Follow-Up Studies Gastrointestinal Hemorrhage - etiology Genital system. Mammary gland Humans Male Medical sciences Middle Aged prostate cancer Quality of Life Radiation Injuries - complications Radiotherapy, Conformal - adverse effects Radiotherapy, Conformal - methods Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Rectum - radiation effects Urinary Bladder - radiation effects |
Title | Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer : Preliminary results on late toxicity and quality of life |
URI | https://www.ncbi.nlm.nih.gov/pubmed/11704322 https://search.proquest.com/docview/18211882 |
Volume | 51 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bitswEBVpFkqhlN6bXrZ66MMuwalsy7Hdt6Vkd-leWtqE5s3IlkwNqR2cBJr9nv5Nf6ozlnwJ3dLLizFOZAXOiTQzmjNDyCuleJqwxLXg89DiWL019rEQspROIFxfshQFzheX49MZfzf35r3ej07W0mYdj5Kra3Ul_4MqPANcUSX7D8g2L4UHcA_4whUQhutfYfzpCxjPVlJgIkZV-CHHDAvrayGxKReYkqWQmZFYVaf6PhuebFG_6Iw8vFuqcpiWWtuA8QHMOax2t-xKYf2AotIbYWZYoqp-kh9Ktaj6gJXbITjqm4U-bsDZwIr9liVo1GMsXos1q-P7RZbu5BvtBiE7pSvw1xoLNk8aFU3cCmp0GKZz_LRUGKXpBBPx6EhJk1Hc7iYL09Jz0oZuMdCEHYp0ZdGpSZys4x82CgG1ArTRfcFOwrRis17TTRHbrBuwqBboUDcRNHt9qLsz_rKN6IjGqnk1AIQNDcB2ggXRCtq9s84XuHwfHc_Oz6PpZD69QfYcP_T8Ptk7Ovv4-awxDGxTFLx-aysoe91OdcDsQzPNjql0eylWAH-q26383h-q7KLpXXLHODT0SLPzHump_D65eWFSNh6Q712S0mtISrskpQc-oydbKtYUKIp3QFFaU_SQAkFpQ1BaE5Rqgr6hHXpSQ09a5BTnoTU9KdCTGnrSIqVIz4dkdjyZvj21TGsQK-Gus7ZCGUsM4TMVe0oqj0vfFQK871Q64yDlgsXj0FM2Y4JJl8fgtKQ2DPK5Fyjhpe4j0s-LXD0h1FWhHXKwm0OwdAXjIomdUAZSuAkDb0AMyKhGIVrqCjBRmxoJsEUIW8TsqIItCgZkfwerdhRHUe7YGZCXNXgRLOZ4QidyVWxWETj74PAH8I3HGtN2rO1j8Uzn6R_HPiO32r_Jc9Jflxv1AgzndbxvCPkT_P7G9w |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Short-course+intensity-modulated+radiotherapy+%2870+Gy+at+2.5+Gy+per+fraction%29+for+localized+prostate+cancer%3A+Preliminary+results+on+late+toxicity+and+quality+of+life&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Kupelian%2C+PA&rft.au=Reddy%2C+CA&rft.au=Klein%2C+E+A&rft.au=Willoughby%2C+T+R&rft.date=2001-11-15&rft.issn=0360-3016&rft.volume=51&rft.issue=4&rft.spage=988&rft.epage=993&rft_id=info:doi/10.1016%2Fs0360-3016%2801%2901730-8&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0360-3016&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0360-3016&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0360-3016&client=summon |